600436: Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) catalogue of feasibility study report of great health intelligent park project
Chapter I General Introduction 1-1.1 Overview 1-1.2 background of the project, necessity and economic significance of investment 1-2 1.3 preparation basis and principles 1-5 1.4 scope and division of labor of feasibility study 1-5 1.5 overview of feasibility study 1-6 1.6 main economic benefit analysis indicators 1-6 1.7 conclusion of feasibility study 1-7 1.8 main problems and suggestions 1-8 Chapter II market demand forecast 2-1 2.1 Overview 2-1 2.2 current situation and technology development trend at home and abroad 2-1 2.3 market demand forecast 2-2.4 conclusion 2-3 Chapter III plant construction conditions and site scheme 3-1 3.1 Overview 3-1 3.2 plant construction conditions 3-1 3.3 current situation and cooperation conditions of public works 3-2 3.4 conclusion 3-2 Chapter IV engineering design scheme 4-1 4.1 project scope 4-1 4.2 general layout and transportation 4-1 4.3 Architecture 4-3 4.4 structure 4-15 4.5 heating, ventilation and air conditioning 4-18 4. 6 power supply 4-25 4.7 water supply and drainage 4-30 4.8 automatic control and weak current 4-38 4.9 thermal power 4-46 Chapter V project construction implementation planning 5-1 5.1 construction contents and quantities 5-1.5.2 project implementation schedule 5-1 5.3 main time nodes of the project 5-2 Chapter VI investment estimation and fund raising 6-1
6.1 Project Overview 6-1 6.2 preparation scope of investment estimation 6-2 6.3 building area 6-4 6.4 main basis for determining price, quota and cost 6-4 6.5 description of relevant matters 6-4 6.6 financing 6-5 Chapter VII project economic evaluation 7-1 7.1 evaluation basis and principles 7-1 7.2 financial analysis 7-1 7.3 uncertainty analysis 7-2 7.4 conclusion of Engineering Economic Analysis 7-2
Chapter I General
1-1.1 general
1.1.1 project name, sponsor and person in charge
Project Name: Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) great health intelligent park project
Employer: Zhangzhou Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) Pharmaceutical Co., Ltd
Person in charge: Lin weiqi
Prepared by: Jilin Pharmaceutical Design Institute Co., Ltd
Person in charge: Han Wenyi
1.1.2 company profile
Zhangzhou Pianzihuang Pharmaceutical Co., Ltd. is a national high-tech enterprise, a national technological innovation demonstration enterprise (the only one in the pharmaceutical industry in Fujian Province), a Chinese time-honored enterprise, a national civilized unit and a national quality benchmark focusing on pharmaceutical manufacturing and R & D, and won the (sixth) Fujian provincial government quality award. It was restructured and established in December 1999 and listed on the Shanghai Stock Exchange in June 2003. Its current share capital is 603 million and its market value exceeds 200 billion, ranking first in the traditional Chinese medicine sector of listed companies. At present, the company has 1 Research Institute, 46 holding subsidiaries and 9 joint-stock companies, with about 2600 employees, operating 6 categories and more than 470 product series. Among them, the core product pianzi Huang is a national first-class protected variety of traditional Chinese medicine. Its traditional production skills have been listed in the national intangible cultural Heritage list, ranking in the forefront of the export of single varieties of Chinese patent medicine in China for many consecutive years, Known as the “Chinese symbol” of the “maritime Silk Road”.
In recent years, the company adheres to the principle of innovation, inheritance and development of traditional Chinese medicine, actively practices the national strategy of “healthy China” and implements the strategy of “multi-core drive and two-way development”, that is, to make pianzi Huang better, expand Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) brand Angong Niuhuang Pill and strengthen pianzi Huang cosmetics; Tap the potential inward, improve quality and efficiency, and realize Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) high-quality development; Make use of Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) ‘s brand advantages, capital advantages and resource advantages, actively find suitable targets, and steadily carry out extension M & A, in order to achieve Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) high-quality leapfrog development. From 2015 to 2020, the company achieved a total revenue of 24.923 billion yuan, a total profit of 7.047 billion yuan and a net profit of 5.961 billion yuan. The average annual compound growth rate of the above indicators exceeds 30%, and the average annual return on net assets reaches more than 20%, which is higher than the advantageous enterprises in the industry and becomes the leader in the industry.
In the first half of 2021, the company achieved a revenue of 3.849 billion yuan, an increase of 18.56%; The total profit was 1.344 billion yuan, an increase of 29.31%; The net profit was 1.142 billion yuan, an increase of 29.24%, another record high in the same period. In 2021, the company’s total operating revenue is expected to exceed 8 billion yuan and its net profit is expected to exceed 2 billion yuan. The company won the “listed company most respected by investors”, “China’s top 20 most competitive pharmaceutical listed companies”, “China’s listed company Jinniu most investment value award”, etc, The board of directors of the company was awarded “Tianma Award for investor relations of Chinese listed companies – best board of directors”, “Tianma Award for investor relations of Chinese listed companies – Best investor relations” and “golden round table Award for board of directors of Chinese listed companies – special contribution to corporate governance”, which fully demonstrated the industry’s outstanding business strategy, excellent brand image High recognition of excellent financial performance. By the end of 2021, the market value of the company’s shares exceeded 200 billion yuan, creating wealth for the society, creating value for investors and contributing to local economic development. The company won the honorary title of “the sixth national civilized unit” in 2020, further consolidated and improved the achievements in the establishment of enterprise spiritual civilization and helped the enterprise develop with high quality, It was honored as the “national advanced collective in combating covid-19 pneumonia epidemic in science and technology system”, “outstanding enterprise in performing social responsibility in traditional Chinese medicine industry in 2021”, “national advanced enterprise in building water-saving cities” and “Fujian patriotism education base”.
Seize the day and live up to your youth. The company will conscientiously implement the spirit of a series of important instructions of the general secretary of Xi Jinping on the development of traditional Chinese medicine, adhere to the principle of making medicine with morality, promoting morality with medicine, adhering to the spirit of craftsmanship as a big country, and forge a prosperous industry with the will of innovation and entrepreneurship, so that “time-honored brands” have “new content”, show “new highlights” and radiate “new advantages”, Move forward for healthy China 2030.
1.2 background of the project, necessity and economic significance of investment
1.2.1 background of project proposal
The report of the 19th CPC National Congress puts forward that “people’s health is an important symbol of national prosperity and national prosperity”. Traditional Chinese medicine is the treasure of China’s traditional medicine and traditional culture. In the new era, we should focus on the inheritance, innovation and development of traditional Chinese medicine. In recent years, the combination of traditional Chinese medicine and modern medicine has formed a medical science system complementary to western medicine, and has developed into one of the few systematic modern economic industries with the advantages of independent intellectual property rights in China. It is an important part of the national strategic emerging industry.
China one belt, one road, China’s development plan (2016-2030 years), the 2016-2020 year plan for the development of Chinese medicine, the 13th Five-Year plan for the development of Chinese medicine, the guide for the development of pharmaceutical industry, the white paper of Chinese medicine and the outline of the 2030 plan for healthy China, were introduced in 2016. The opinions on promoting the inheritance, innovation and development of traditional Chinese medicine and other industrial policies of traditional Chinese medicine were intensively released. On July 1, 2017, the official implementation of the law on traditional Chinese medicine defined the important position of traditional Chinese medicine in the form of law, adhered to both support and standardization, and at the same time, in the access of traditional Chinese medicine clinics and traditional Chinese medicine doctors Traditional Chinese medicine management has reformed and innovated the existing management system. The 14th five year plan also emphasizes that both traditional Chinese and Western medicine should be emphasized and the cause of traditional Chinese medicine should be vigorously developed. In October 2019, the State Council issued the opinions on promoting the inheritance, innovation and development of traditional Chinese medicine, which defined the goal, direction and specific measures for the inheritance, innovation and development of traditional Chinese medicine. Subsequently, the local governments of Yunnan, Guangdong, Sichuan and Guangxi Zhuang Autonomous Region also responded positively and introduced corresponding measures to promote the development of local traditional Chinese medicine industry in combination with local characteristics. In the novel coronavirus pneumonia outbreak in 2020, Chinese medicine became the mainstay of the epidemic. It is the outstanding contribution of traditional Chinese medicine under the epidemic situation that has accelerated the pace of inheritance, innovation and development. On September 27, 2020, the registration classification and application data requirements of traditional Chinese medicine were significantly updated. After the update, traditional Chinese medicine innovative drugs were listed as the first category, opening the wave of traditional Chinese medicine innovation. 2021 ushered in the outbreak of the implementation of traditional Chinese medicine policies. A series of heavy policies such as the lifting of restrictions on some traditional Chinese medicine in the medical insurance catalogue, the completion of the pilot of traditional Chinese medicine formula granules, the moderate price reduction of centralized purchase of traditional Chinese medicine in Hubei, and the guidance on medical insurance supporting the inheritance, innovation and development of traditional Chinese medicine have been implemented one after another, It can be seen that the national support policy for traditional Chinese medicine has gradually transitioned from the top-level design to the implementation stage, which has strong consistency and releases a strong positive signal.
Under the background of the above industry development and policy support, in order to achieve future development, the company needs to ensure the production of high-profit products through product structure adjustment, rely on the construction of Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) great health intelligent park, absorb the most advanced scientific and technological achievements and practical technologies at home and abroad, and gather top scientific research institutions and scientific and technological leaders for industrial development, The National Engineering Research Center and modern intelligent manufacturing research platform of traditional Chinese medicine will be built in the park, including four centers: R & D center, testing center, standard center and achievement transformation center. In addition to serving Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) pharmaceutical industry and other enterprises in the park, the above centers and platforms will also provide services for Fujian and surrounding provinces.
1.2.2 necessity and economic significance of project implementation
1 necessity of project implementation
After years of development, the Chinese sales market of the pharmaceutical industry has entered the order sales mode. Therefore, pharmaceutical enterprises must have the ability to flexibly respond to the changing market, meet the market demand, shorten the product manufacturing cycle and improve the capital turnover rate. In order to seize market opportunities under the support of national industrial policies, the company must further expand production capacity construction, enrich product varieties, increase R & D investment and market development. Production facilities must be used as support for production capacity improvement. The company’s current production workshop is located in Amber Road, Xiangcheng District, Zhangzhou city. Due to the long construction time, after years of development, The site is relatively small, and the plant area, process layout and equipment capacity can no longer meet the development needs of the enterprise and the market, resulting in a certain degree of restriction on the expansion of the company’s capacity. The construction of Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) great health intelligent park can not only solve these problems restricting the development of the company, but also further improve the R & D capacity, automation and intelligence level of the company, improve the efficiency of product quality management, fully meet the market demand and ensure the long-term and stable development of the enterprise through the construction of high-level research institutes and modern production workshops in the park.
The testing center is recognized by China National Accreditation Service for conformity assessment (CNAs) and is the only pharmaceutical enterprise in Fujian Province recognized by CNAs. “Analysis and Research on complex effects of representative prescriptions for promoting blood circulation and removing blood stasis based on integration strategy” won the first prize of science and technology award of Chinese society of traditional Chinese medicine in 2021. Driven by science and technology, the company has surpassed the high-quality development of the enterprise. The company has been rated as “national high-tech enterprise”, “national enterprise technology center”, “national technological innovation demonstration enterprise”, “national quality benchmark” and other honors. The construction of four regional central platforms in the park will have more far-reaching social benefits:
R & D Center
In accordance with the principle of “not for me, but for my use”, the company adheres to the dominant position of R & D, strengthens the allocation of R & D resources, and builds a three-level R & D platform in the smart Park project park. That is, it has a number of high-level independent core R & D platforms such as national enterprise technology center, postdoctoral scientific research workstation, academician expert workstation, Fujian Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) natural medicine R & D enterprise key laboratory and Fujian classic traditional Chinese medicine compound Engineering Research Center, and introduces R & D technicians in various professional disciplines
